AU656938B2 - TNF inhibitors - Google Patents

TNF inhibitors

Info

Publication number
AU656938B2
AU656938B2 AU91159/91A AU9115991A AU656938B2 AU 656938 B2 AU656938 B2 AU 656938B2 AU 91159/91 A AU91159/91 A AU 91159/91A AU 9115991 A AU9115991 A AU 9115991A AU 656938 B2 AU656938 B2 AU 656938B2
Authority
AU
Australia
Prior art keywords
tnf
xanthine
group
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU91159/91A
Other languages
English (en)
Other versions
AU9115991A (en
Inventor
Klaus Max Esser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU9115991A publication Critical patent/AU9115991A/en
Application granted granted Critical
Publication of AU656938B2 publication Critical patent/AU656938B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU91159/91A 1990-11-21 1991-11-20 TNF inhibitors Ceased AU656938B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61647990A 1990-11-21 1990-11-21
PCT/US1991/008734 WO1992009203A1 (en) 1990-11-21 1991-11-20 Tnf inhibitors
US616479 2000-07-14

Publications (2)

Publication Number Publication Date
AU9115991A AU9115991A (en) 1992-06-25
AU656938B2 true AU656938B2 (en) 1995-02-23

Family

ID=24469639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU91159/91A Ceased AU656938B2 (en) 1990-11-21 1991-11-20 TNF inhibitors

Country Status (14)

Country Link
EP (1) EP0558659A4 (OSRAM)
JP (1) JP3204971B2 (OSRAM)
KR (1) KR930702896A (OSRAM)
AP (1) AP259A (OSRAM)
AU (1) AU656938B2 (OSRAM)
CA (1) CA2096623A1 (OSRAM)
HU (1) HUT65838A (OSRAM)
IE (1) IE914034A1 (OSRAM)
IL (1) IL100088A (OSRAM)
MX (1) MX9102173A (OSRAM)
NZ (1) NZ240644A (OSRAM)
TW (1) TW222001B (OSRAM)
WO (1) WO1992009203A1 (OSRAM)
ZA (1) ZA919178B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
AU7376394A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
AU2003289898A1 (en) * 2002-11-27 2004-06-18 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
RU2395511C2 (ru) * 2004-02-14 2010-07-27 Смитклайн Бичам Корпорейшн Новые соединения
PT1781657E (pt) 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
BR112017007194B1 (pt) 2014-10-09 2023-11-07 Guangdong Raynovent Biotech Co., Ltd Compostos de hidroxil purina e uso dos mesmos
ES2784826T3 (es) 2015-10-29 2020-10-01 Guangdong Raynovent Biotech Co Ltd Forma cristalina de un compuesto de 4H-pirazol[1,5-]benzimidazol, procedimiento de preparación de la misma e intermediario de la misma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389282A2 (en) * 1989-03-23 1990-09-26 BEECHAM - WUELFING GmbH & Co. KG Xanthinederivatives, process for their preparation and their pharmaceutical use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US757328A (en) * 1903-02-07 1904-04-12 Boehringer & Soehne Art of preparing xanthin derivatives.
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.
DE2944568A1 (de) * 1979-11-05 1981-05-14 Institut für industrielle Pharmazie F + E GmbH, 8750 Aschaffenburg Pharmazeutische zubereitung
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
FI891419A7 (fi) * 1989-03-23 1990-09-24 Tampella Oy Ab Anordning i en gaengoeppningsanordning foer borrmaskineri.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389282A2 (en) * 1989-03-23 1990-09-26 BEECHAM - WUELFING GmbH & Co. KG Xanthinederivatives, process for their preparation and their pharmaceutical use

Also Published As

Publication number Publication date
EP0558659A4 (en) 1993-10-20
IL100088A (en) 1995-07-31
IE914034A1 (en) 1992-06-03
EP0558659A1 (en) 1993-09-08
ZA919178B (en) 1992-10-28
CA2096623A1 (en) 1992-05-22
AP9100335A0 (en) 1992-01-31
HU9301509D0 (en) 1993-11-29
NZ240644A (en) 1994-08-26
HUT65838A (en) 1994-07-28
JPH06506192A (ja) 1994-07-14
AU9115991A (en) 1992-06-25
IL100088A0 (en) 1992-08-18
AP259A (en) 1993-06-03
WO1992009203A1 (en) 1992-06-11
KR930702896A (ko) 1993-11-29
TW222001B (OSRAM) 1994-04-01
MX9102173A (es) 1992-06-01
JP3204971B2 (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
US5420154A (en) TNF inhibitors
AU656938B2 (en) TNF inhibitors
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
EP1040831A2 (en) Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
PT1505973E (pt) Combinações para o tratamento de mieloma múltiplo
JPH11510156A (ja) キノロン類およびその医療上の使用
JP2001504130A (ja) キサンチン類およびこれらの治療的使用
EP0572537B1 (en) Cytokine inhibitors
CN1972684A (zh) 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
JP2023528722A (ja) サイトカインストーム症候群及び関連疾患を治療する方法
US5547979A (en) TNF inhibition
JP5148478B2 (ja) マラリア治療用のフェロキンとアーテミシニン誘導体との組合せ
WO1993016699A1 (en) Tnf inhibitors
CN1260784A (zh) 作为pdeiv和tnf抑制剂的喹啉衍生物
WO2001058443A1 (fr) INHIBITEURS DE TNF-$g(a)
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
RU2665383C9 (ru) Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
JPS63310867A (ja) 抗鬱病剤作用を有する新規な結合生成物
JP2002514177A (ja) Ａｉｄｓ治療薬の製造へのｐｋｃ阻害剤の使用
JPH10503178A (ja) Ｈｉｖ感染のための組合わせ療法
PT100429B (pt) Uso de derivados da xantina na preparacao de um medicamento para inibicao da producao de factor de necrose tumoral
JPH0651622B2 (ja) インタロイキン‐１産生の阻止剤としての５―ヒドロキシおよび５―メトキシ２―アミノピリミジンの誘導体
JPH08502044A (ja) ヒトウイルス感染の治療
JP2002514178A (ja) Ｈｉｖ感染が関与する中枢神経系疾患の治療用薬剤の製造を目的とするｐｋｃ阻害剤の使用
CZ52199A3 (cs) Použití PKC inhibitorů pro výrobu léčiva pro léčbu nemocí centrálního nervového systému spojených s HIV infekcí